Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Norway study: routine endometrial cancer screening "inadvisable"

This article was originally published in Clinica

Executive Summary

Despite an incidence of 500 cases of endometrial cancer in Norway each year, there is no evidence to suggest that mass screening would reduce this figure, says Helga Salvesen, from the gynaecological clinic at Haukeland Hospital in Bergen. In an article published this month in the Journal of the Norwegian Doctors' Association (Tidsskr Nor Laegeforen 2002; 122: 1767), Dr Salvesen conceded that the relatively high incidence, the possibility of effective, early-stage treatment of the disease, combined with the fact that the endometrial mucus membrane is easily accessible for examination, do indicate that screening could be beneficial. "[However] the quality of available methods is too low for a person to be declared either apparently healthy or ill with a reasonable degree of accuracy in a mass screening of the population," she added.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel